Plant Derived Analgesics Market Size is valued at US$ 4.0 Bn in 2024 and is predicted to reach US$ 7.87 Bn by the year 2034 at an 7.1% CAGR during the forecast period for 2025-2034.
Analgesics made from plants are used to treat headaches, inflammation, muscular injuries, and arthritis. The usage for pain treatment is supported by mechanisms such as suppression of peripheral mediators, modification of opioid and cholinergic pathways, and anti-inflammatory properties; nevertheless, some adverse effects and the necessity of clinical evaluation are noted.
Relevant examples range from morphine derived from Papaver somniferum to botanicals like turmeric, ginger, lavender, peppermint, and cinnamon employed for inflammatory and central analgesic effects. They are administered orally or topically as decoctions, macerations, poultices, or standardized extracts, including powders, tinctures, and pills used in formulations. The global market for Plant Derived Analgesics is expanding due to the rising awareness of herbal medicine, fewer side effects, and increasing acceptance of plant-based treatments.
The rising awareness of herbal medicine is another element propelling the plant derived analgesics market. The plant derived analgesics market is expanding because rising awareness of herbal medicine is driving the plant derived analgesics market as people seek natural, safer, and chemical-free pain relief options with fewer side effects and proven therapeutic benefits.
About 14.1% of female university students utilized herbal remedies (such as ginger, chamomile, and cinnamon) for menstruation discomfort (primary dysmenorrhea), compared to >50% who used traditional NSAIDs or acetaminophen. However, regulatory complexity and inconsistent global standards are some of the obstacles impeding the growth of the plant derived analgesics sector. Over the course of the forecast period, opportunities for the plant derived analgesics market will be created by gradual policy evolution regarding cannabis-based medicines.
Some of the Key Players in Plant Derived Analgesics Market:
· Pfizer Inc.
· Mallinckrodt Pharmaceuticals
· Teva Pharmaceutical Industries Ltd.
· Johnson & Johnson
· NOW Foods
· Purdue Pharma L.P.
· Sun Pharmaceutical Industries Ltd.
· Endo Pharmaceuticals Inc.
· GW Pharmaceuticals (Jazz Pharmaceuticals)
· Canopy Growth Corporation
· Charlotte's Web Holdings, Inc.
· Tilray Brands, Inc.
· Curaleaf Holdings, Inc.
· Hikma Pharmaceuticals PLC
· Amneal Pharmaceuticals, Inc.
· Others
The plant derived analgesics market is segmented product type, formulation type, application, and sales channel. By product type, the market is segmented into morphine, codeine, salicin, cannabinoids (CBD), and curcumin. By formulation type, the market is segmented into tablets, capsules, creams, injectable forms, and oils. By application, the market is segmented into chronic pain management, acute pain relief, post-surgical pain, and neuropathic pain. By sales channel, the market is segmented into hospitals, clinics, retail sales, online sales, and hypermarkets & supermarkets.
The morphine segment led the plant derived analgesics market in 2024. This convergence is fueled by its superior analgesic capabilities, including potent discomfort relief, well-established clinical protocols, and thorough healthcare integration which enables healthcare organizations to achieve optimal pain control in a variety of acute and chronic pain environments. Morphine products stand out due to their extensive safety documentation, demonstrated clinical efficacy, and integration with multimodal pain management techniques that improve patient outcomes while upholding the highest standards of comfort appropriate for a variety of surgical, cancer, and chronic pain applications.
The tablets segment represents the largest and fastest-growing formulation type in the plant-derived analgesics market. This growth is driven by the broad acceptance of oral solid dosage forms, which offer superior patient convenience, dose precision, and treatment adherence, ensuring consistent therapeutic outcomes. Tablets also align with manufacturing efficiency and scalability standards favored by pharmaceutical producers. Moreover, increasing investment in controlled-release technologies and advanced formulation engineering aimed at optimizing pain management therapies further strengthens the dominance of this segment across both prescription and over-the-counter analgesic markets.
North America dominated the plant derived analgesics market in 2024. The United States is at the forefront of this expansion. This is due to significant demand for herbal-based pain relief products and high consumer awareness of natural healthcare options. Market dominance is supported by the region's sophisticated pharmaceutical sector, continuing research on chemicals derived from plants, and growing demand for non-opioid substitutes. The robust market presence in North America is also a result of favorable laws, the general accessibility of herbal supplements, and the rising demand for environmentally friendly, plant-based goods.
The Asia-Pacific region is witnessing the strongest and fastest growth in the plant-derived analgesics market, primarily driven by the widespread acceptance of long-established traditional medical systems such as Traditional Chinese Medicine (TCM), Ayurveda, and Kampo. These practices are increasingly integrated with modern healthcare, fueling demand for plant-based pain management solutions. Government initiatives including funding programs, simplified regulatory frameworks, and support from organizations like the WHO Traditional Medicine Center and India’s AYUSH guidelines further accelerate market development. Additionally, rapid urbanization and a rising preference for natural pain relief alternatives sustain the region’s leading CAGR and long-term growth outlook.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 4.0 Bn |
| Revenue Forecast In 2034 | USD 7.87 Bn |
| Growth Rate CAGR | CAGR of 7.1% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Product Type, By Formulation Type, By Application, By Sales Channel, and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; Germany; The UK; France; Italy; Spain; Rest of Europe; China; Japan; India; South Korea; Southeast Asia; Rest of Asia Pacific; Brazil; Argentina; Mexico; Rest of Latin America; GCC Countries; South Africa; Rest of the Middle East and Africa |
| Competitive Landscape | Pfizer Inc., Mallinckrodt Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, NOW Foods, Purdue Pharma L.P., Sun Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., GW Pharmaceuticals (Jazz Pharmaceuticals), Canopy Growth Corporation, Charlotte's Web Holdings, Inc., Tilray Brands, Inc., Curaleaf Holdings, Inc., Hikma Pharmaceuticals PLC, and Amneal Pharmaceuticals, Inc. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Plant Derived Analgesics Market by Product Type
· Morphine
· Codeine
· Salicin
· Cannabinoids (CBD)
· Curcumin
Plant Derived Analgesics Market by Formulation Type
· Tablets
· Capsules
· Creams
· Injectable Forms
· Oils
Plant Derived Analgesics Market by Application
· Chronic Pain Management
· Acute Pain Relief
· Post-Surgical Pain
· Neuropathic Pain
Plant Derived Analgesics Market by Sales Channel
· Hospitals
· Clinics
· Retail Sales
· Online Sales
· Hypermarkets & Supermarkets
Plant Derived Analgesics Market by Region
North America-
· The US
· Canada
Europe-
· Germany
· The UK
· France
· Italy
· Spain
· Rest of Europe
Asia-Pacific-
· China
· Japan
· India
· South Korea
· Southeast Asia
· Rest of Asia Pacific
Latin America-
· Brazil
· Argentina
· Mexico
· Rest of Latin America
Middle East & Africa-
· GCC Countries
· South Africa
· Rest of the Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Plant Derived Analgesics Market Snapshot
Chapter 4. Global Plant Derived Analgesics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global Plant Derived Analgesics Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Plant Derived Analgesics Market Industry Trends
Chapter 5. Plant Derived Analgesics Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. Market Share by Product, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Morphine
5.2.2. Codeine
5.2.3. Salicin
5.2.4. Cannabinoids (CBD)
5.2.5. Curcumin
Chapter 6. Plant Derived Analgesics Market Segmentation 2: By Application, Estimates &
Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following
Application:
6.2.1. Chronic Pain Management
6.2.2. Acute Pain Relief
6.2.3. Post-Surgical Pain
6.2.4. Neuropathic Pain
Chapter 7. Plant Derived Analgesics Market Segmentation 3: By Formulation Type, Estimates & Trend Analysis
7.1. Market Share by Formulation Type, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Formulation Type:
7.2.1. Tablets
7.2.2. Capsules
7.2.3. Creams
7.2.4. Injectable Forms
7.2.5. Oils
Chapter 8. Plant Derived Analgesics Market Segmentation 4: By Sales Channel, Estimates & Trend Analysis
8.1. Market Share by Sales Channel, 2024 & 2034
8.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Sales Channel:
8.2.1. Hospitals
8.2.2. Clinics
8.2.3. Retail Sales
8.2.4. Online Sales
8.2.5. Hypermarkets & Supermarkets
Chapter 9. Plant Derived Analgesics Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Plant Derived Analgesics Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Product, 2021-2034
9.2.3. North America Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
9.2.4. North America Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Formulation Type, 2021-2034
9.2.5. North America Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Sales Channel, 2021-2034
9.3. Europe
9.3.1. Europe Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Product, 2021-2034
9.3.3. Europe Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
9.3.4. Europe Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Formulation Type, 2021-2034
9.3.5. Europe Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Sales Channel, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Product, 2021-2034
9.4.3. Asia Pacific Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
9.4.4. Asia Pacific Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Formulation Type, 2021-2034
9.4.5. Asia Pacific Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Sales Channel, 2021-2034
9.5. Latin America
9.5.1. Latin America Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Product, 2021-2034
9.5.3. Latin America Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
9.5.4. Latin America Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Formulation Type, 2021-2034
9.5.5. Latin America Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Sales Channel, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Product, 2021-2034
9.6.3. Middle East & Africa Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
9.6.4. Middle East & Africa Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Formulation Type, 2021-2034
9.6.5. Middle East & Africa Plant Derived Analgesics Market Revenue (US$ Mn) Estimates and Forecasts by Sales Channel, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Pfizer Inc.
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Mallinckrodt Pharmaceuticals
10.2.3. Teva Pharmaceutical Industries Ltd.
10.2.4. Johnson & Johnson
10.2.5. NOW Foods
10.2.6. Purdue Pharma L.P.
10.2.7. Sun Pharmaceutical Industries Ltd.
10.2.8. Endo Pharmaceuticals Inc.
10.2.9. GW Pharmaceuticals (Jazz Pharmaceuticals)
10.2.10. Canopy Growth Corporation
10.2.11. Charlotte's Web Holdings, Inc.
10.2.12. Tilray Brands, Inc.
10.2.13. Curaleaf Holdings, Inc.
10.2.14. Hikma Pharmaceuticals PLC
10.2.15. Amneal Pharmaceuticals, Inc.